Articles by Todd L. Cecil - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Todd L. Cecil

Todd L. Cecil


Todd L. Cecil, PhD, is the vice-president of the Department of Standards Development at the US Pharmacopeia.

Articles
Regulatory Compliance with One Eye on Cost
December 2, 2011

A new book attempts to reduce the confusion and costs associated with regulatory compliance.

Colloids Book Helps and Confuses the Reader
January 2, 2011

Poor organization makes it hard for readers to find the helpful information in a recent book.

Breaking Down Barriers to Oral Delivery
February 2, 2010

A recent book provides information about formulating biopharmaceuticals that is easy to swallow.

Ever Vigilant (A Pharmacovigilance Book Review)
April 2, 2009

In a recent book, UK regulators explain how to establish a pharmacovigilance system.

Inside USP: Revising USP General Notices
August 2, 2007

USP is revising key documents to make them easier to use.

Public Comment and Expert Oversight: The Cornerstones of USP Standards Development
May 2, 2007

USP exercises a vigorous standards-setting process that draws on both public comments and meticulous scientific review.

USP's Work Plan and New Revision Approaches
October 2, 2006

Efforts to solicit new monographs have fallen behind the rate of NDA approvals, while analytical techniques have become outdated because of advances in analytical technologies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here